Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide

Heart Rhythm

Volumn 9, Issue 5, 2012, Pages 776-781

  Schimpf, Rainer ^a   Veltmann, Christian ^a   Papavassiliu, Theano ^a   Rudic, Boris ^a   Göksu, Turgay ^a   Kuschyk, Jürgen ^a   Wolpert, Christian ^b   Antzelevitch, Charles ^c   Ebner, Alois ^d   Borggrefe, Martin ^a   Brandt, Christian ^d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KLINIKUM LUDWIGSBURG   (Germany)

^c MASONIC MEDICAL RESEARCH LABORATORY   (United States)

^d EPILEPSY CENTER BETHEL   (Germany)

Author keywords

Drug induced QT interval shortening; Proarrhythmia; Rufinamide; Short QT syndrome; sudden cardiac death; SUDEP

Indexed keywords

ETIRACETAM; LAMOTRIGINE; RUFINAMIDE; VALPROIC ACID;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG APPROVAL; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MONITORING; EPILEPSY; FEMALE; FOLLOW UP; HUMAN; LENNOX GASTAUT SYNDROME; MALE; PRIORITY JOURNAL; QT INTERVAL; SHORT QT INTERVAL;

ADMINISTRATION, ORAL; ADULT; AGED; ANTICONVULSANTS; ARRHYTHMIAS, CARDIAC; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTELLECTUAL DISABILITY; MALE; MIDDLE AGED; SPASMS, INFANTILE; TRIAZOLES; YOUNG ADULT;

EID: 84859948014     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2012.01.006     Document Type: Article

References (45)

1. Gussak I, Brugada P, Brugada J, et al. Idiopathic short QT interval: a new clinical syndrome? Cardiology 2000;94:99-102. (Pubitemid 32110328)
2. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: a familial cause of sudden death. Circulation 2003;108:965-970. (Pubitemid 37048226)
3. Brugada R, Hong K, Dumaine R, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004;109:30-35. (Pubitemid 38056017)
4. Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007;115:442-449. (Pubitemid 46184195)
5. Templin C, Ghadri JR, Rougier JS, et al. Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6). Eur Heart J 2011;32:1077-1088.
6. Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol 2011;58:587-595.
7. Bellet S, Finkelstein D. Significance of QT prolongation in the electrocardiogram: based on the study of 168 cases. Am J Med Sci 1951;222:263-278.
8. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348:1866-1874. (Pubitemid 36532312)
9. Food and Drug Administration, HHS. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Fed Regist 2005;70:61134-61135.
10. Shah RR. Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives. Br J Pharmacol 2010;159:58-69.
11. Garberoglio L, Giustetto C, Wolpert C, Gaita F. Is acquired short QT due to digitalis intoxication responsible for malignant ventricular arrhythmias? J Electrocardiol 2007;40:43-46. (Pubitemid 44958601)
12. Marchand M, Critchley D, Nagy C, Fuseau E. The effect of rufinamide concentration on the QT interval in healthy subjects treated during 18 days with multiple ascending doses: a population PKPD analysis. In: Annual Meeting of the Population Approach Group in Europe; 2005. Abstract A785.
13. European Medicines Agency. Inovelon® (rufinamide) product information; 2009. Available at: http://wwwemaeuropaeu/ema/indexjsp?curl=pages/ medicines/human/medicines/000660/human-med-000837jsp&murl=menus/medicines/ medicinesjsp&mid=WC0b01ac058001d124. Accessed August 15, 2011.
14. May TW, Boor R, Rambeck B, et al. Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit 2011;33:214-221.
15. Postema PG, De Jong JS, Van der Bilt IA, Wilde AA. Accurate electrocardiographic assessment of the QT interval: teach the tangent. Heart Rhythm 2008;5:1015-1018.
16. Antzelevitch C, Yan GX, Shimizu W. Transmural dispersion of repolarization and arrhythmogenicity: the Brugada syndrome versus the long QT syndrome. J Electrocardiol 1999;32:158-165. (Pubitemid 30100122)
17. Kenneback G, Bergfeldt L, Vallin H, Tomson T, Edhag O. Electrophysiologic effects and clinical hazards of carbamazepine treatment for neurologic disorders in patients with abnormalities of the cardiac conduction system. Am Heart J 1991;121:1421-1429.
18. Wyte CD, Berk WA. Severe oral phenytoin overdose does not cause cardiovascular morbidity. Ann Emerg Med 1991;20:508-512.
19. DeSilvey DL, Moss AJ. Primidone in the treatment of the long QT syndrome: QT shortening and ventricular arrhythmia suppression. Ann Intern Med 1980;93:53-54. (Pubitemid 10072003)
20. Kluger G, Glauser T, Krauss G, et al. Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand 2010;122:202-208.
21. Cheng-Hakimian A, Anderson GD, Miller JW. Rufinamide: pharmacology, clinical trials, and role in clinical practice. Int J Clin Pract 2006;60:1497-1501. (Pubitemid 44560351)
22. Wheless JW, Vazquez B. Rufinamide: a novel broad-spectrum antiepileptic drug. Epilepsy Curr 2010;10:1-106.
23. European Medicines Agency. Inovelon® (rufinamide) scientific information; 2007. Available at: http://wwwemaeuropaeu/docs/en-GB/document- library/EPARScientific-Discussion/human/000660/WC500032940pdf. Accessed December 18, 2011.
24. Holbrook M, Malik M, Shah RR, Valentin JP. Drug induced shortening of the QT/QTc interval: an emerging safety issue warranting further modelling and evaluation in drug research and development? J Pharmacol Toxicol Methods 2009;59:21-28.
25. Raschi E, Poluzzi E, Koci A, Boriani G, De Ponti F. QT-interval shortening in spontaneous reports submitted to the FDA: the need for consensus. Br J Clin Pharmacol 2011;72:839-841.
26. Shah RR, Bjerregaard P, Gussak I. Drug-induced QT interval shortening: an emerging component in integrated assessment of cardiac safety of drugs. J Electrocardiol 2010;43:386-389.
27. Dixon R, Job S, Oliver R, et al. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. Br J Clin Pharmacol 2008;66:396-404.
28. Aurlien D, Tauboll E, Gjerstad L. Lamotrigine in idiopathic epilepsy-increased risk of cardiac death? Acta Neurol Scand 2007;115:199-203. (Pubitemid 46219214)
29. Sicouri S, Antzelevitch C. Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opin Drug Saf 2008;7:181-194. (Pubitemid 351447701)
30. Minoura Y, JM DID, Barajas-Martinez H, et al. Ionic and cellular mechanisms underlying the development of acquired Brugada syndrome in patients treated with antidepressants. J Cardiovasc Electrophysiol 2011.
31. Gao Z, Milnes JT, Choisy SC, et al. The neuroprotective agent sipatrigine blocks multiple cardiac ion channels and causes triangulation of the ventricular action potential. Clin Exp Pharmacol Physiol 2005;32:1088-1096. (Pubitemid 43906819)
32. Kobza R, Roos M, Niggli B, et al. Prevalence of long and short QT in a young population of 41,767 predominantly male Swiss conscripts. Heart Rhythm 2009;6:652-657.
33. Viskin S. The QT interval: too long, too short or just right. Heart Rhythm 2009;6:711-715.
34. Viskin S, Rosso R, Marquez MF, Antzelevitch C. The acquired Brugada syndrome and the paradox of choice. Heart Rhythm 2009;6:1342-1344.
35. Shorvon S, Tomson T. Sudden unexpected death in epilepsy. Lancet 2011.
36. Akalin F, Tirtir A, Yilmaz Y. Increased QT dispersion in epileptic children. Acta Paediatr 2003;92:916-920. (Pubitemid 37088628)
37. Kwon S, Lee S, Hyun M, et al. The potential for QT prolongation by antiepileptic drugs in children. Pediatr Neurol 2004;30:99-101. (Pubitemid 38249342)
38. Tu E, Bagnall RD, Duflou J, Semsarian C. Post-mortem review and genetic analysis of sudden unexpected death in epilepsy (SUDEP) cases. Brain Pathol 2011;21:201-208.
39. Tu E, Waterhouse L, Duflou J, Bagnall RD, Semsarian C. Genetic analysis of hyperpolarization-activated cyclic nucleotide-gated cation channels in sudden unexpected death in epilepsy cases. Brain Pathol 2011;21:692-698.
40. Ueda K, Nakamura K, Hayashi T, et al. Functional characterization of a trafficking- defective HCN4 mutation, D553N, associated with cardiac arrhythmia. J Biol Chem 2004;279:27194-27198. (Pubitemid 38812556)
41. Johnson JN, Tester DJ, Bass NE, Ackerman MJ. Cardiac channel molecular autopsy for sudden unexpected death in epilepsy. J Child Neurol 2010;25:916-921.
42. 2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J Clin Invest 2008;118:2230-2245.
43. Aurlien D, Leren TP, Tauboll E, Gjerstad L. New SCN5A mutation in a SUDEP victim with idiopathic epilepsy. Seizure 2009;18:158-160.
44. Surges R, Scott CA, Walker MC. Enhanced QT shortening and persistent tachycardia after generalized seizures. Neurology 2010;74:421-426.
45. Hesdorffer DC, Tomson T, Benn E, et al. Combined analysis of risk factors for SUDEP. Epilepsia 2011;52:1150-1159.